|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 10/17/17 Cell MedX Corp. 10-Q 8/31/17 59:2.2M Empire Stock Transf… Inc |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 286K
6: EX-10.55 Loan Agreement and Note Payable Dated July 12, HTML 25K
2017, Among Cell Medx Corp., and Richard N. Jeffs
7: EX-10.56 Stock Option Agreement Dated August 24, 2017 Among HTML 65K
Cell Medx Corp. and Yanika Silina
8: EX-10.57 Stock Option Agreement Dated August 24, 2017 Among HTML 65K
Cell Medx Corp. and Da Costa Management Corp.
9: EX-10.58 Stock Option Agreement Dated August 24, 2017 Among HTML 65K
Cell Medx Corp. and John Giovanni Di Cicco
2: EX-31.1 Certification -- §302 - SOA'02 HTML 23K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 23K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 20K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 19K
16: R1 Document and Entity Information HTML 45K
17: R2 Consolidated Balance Sheets HTML 76K
18: R3 Balance Sheets (Parenthetical) HTML 28K
19: R4 Consolidated Statements of Operations HTML 64K
20: R5 Consolidated Statements of Stockholders' Equity HTML 68K
(Deficit)
21: R6 Consolidated Statements of Stockholders' Equity HTML 21K
(Parenthetical)
22: R7 Consolidated Statements of Cash Flows HTML 85K
23: R8 Organization and Nature of Operations HTML 26K
24: R9 Related Party Transactions, Disclosure HTML 46K
25: R10 Equipment, Disclosure HTML 28K
26: R11 Inventory Disclosure HTML 22K
27: R12 Unearned Revenue Disclosure HTML 22K
28: R13 Notes and Advances Payable, Disclosure HTML 57K
29: R14 Share Capital, Disclosure HTML 59K
30: R15 Subsequent Events Disclosure HTML 23K
31: R16 Organization and Nature of Operations: Unaudited HTML 23K
Interim Financial Statements (Policies)
32: R17 Organization and Nature of Operations: Going HTML 23K
Concern (Policies)
33: R18 Related Party Transactions, Disclosure: Schedule HTML 30K
of Amounts Due to Related Parties (Tables)
34: R19 Related Party Transactions, Disclosure: Schedule HTML 35K
of Transactions with Related Parties (Tables)
35: R20 Equipment, Disclosure: Amortization Schedule for HTML 28K
Equipment (Tables)
36: R21 Notes and Advances Payable, Disclosure: Schedule HTML 44K
of Short-term Loans and Advances Outstanding
(Tables)
37: R22 Notes and Advances Payable, Disclosure: Fair HTML 24K
values assumptions of the warrants - Term Loan
Agreement (Tables)
38: R23 Share Capital, Disclosure: Black-Scholes Option HTML 24K
pricing valuation - Stock Options granted August
24, 2017 (Tables)
39: R24 Share Capital, Disclosure: Schedule of Stock HTML 36K
Option Activity (Tables)
40: R25 Share Capital, Disclosure: Schedule of Stock HTML 29K
Options Outstanding (Tables)
41: R26 Share Capital, Disclosure: Schedule of Warrant HTML 26K
Activity (Tables)
42: R27 Share Capital, Disclosure: Schedule of Warrant HTML 27K
Details (Tables)
43: R28 Organization and Nature of Operations: Going HTML 22K
Concern (Details)
44: R29 Related Party Transactions, Disclosure: Schedule HTML 30K
of Amounts Due to Related Parties (Details)
45: R30 Related Party Transactions, Disclosure: Schedule HTML 37K
of Transactions with Related Parties (Details)
46: R31 Equipment, Disclosure: Amortization Schedule for HTML 28K
Equipment (Details)
47: R32 Inventory Disclosure (Details) HTML 24K
48: R33 Unearned Revenue Disclosure (Details) HTML 24K
49: R34 Notes and Advances Payable, Disclosure: Schedule HTML 38K
of Short-term Loans and Advances Outstanding
(Details)
50: R35 Notes and Advances Payable, Disclosure (Details) HTML 42K
51: R36 Share Capital, Disclosure (Details) HTML 21K
52: R37 Share Capital, Disclosure: Schedule of Stock HTML 32K
Option Activity (Details)
53: R38 Share Capital, Disclosure: Schedule of Stock HTML 33K
Options Outstanding (Details)
54: R39 Share Capital, Disclosure: Schedule of Warrant HTML 23K
Activity (Details)
55: R40 Share Capital, Disclosure: Schedule of Warrant HTML 22K
Details (Details)
56: R41 Subsequent Events Disclosure (Details) HTML 27K
58: XML IDEA XML File -- Filing Summary XML 98K
57: EXCEL IDEA Workbook of Financial Reports XLSX 39K
10: EX-101.INS XBRL Instance -- cmxc-20170831 XML 507K
12: EX-101.CAL XBRL Calculations -- cmxc-20170831_cal XML 46K
13: EX-101.DEF XBRL Definitions -- cmxc-20170831_def XML 196K
14: EX-101.LAB XBRL Labels -- cmxc-20170831_lab XML 390K
15: EX-101.PRE XBRL Presentations -- cmxc-20170831_pre XML 355K
11: EX-101.SCH XBRL Schema -- cmxc-20170831 XSD 98K
59: ZIP XBRL Zipped Folder -- 0001393905-17-000315-xbrl Zip 49K
| ex-10.55 |
LOAN AGREEMENT
Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced CDN$25,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on July 12, 2017.
The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) from July 12, 2017. The Borrower is liable for repayment for the Principal Sum and accrued Interest and any costs that the Lender incurs in trying to collect the Principal Sum and the Interest.
The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached form.
| LENDER |
|
BORROWER |
|
| Cell MedX Corp. | |
|
|
|
|
| Per: |
| Per: |
|
|
|
|
|
|
|
|
| /s/ Richard N. Jeffs |
| /s/ Yanika Silina |
|
| Yanika Silina, CFO |
PROMISSORY NOTE
| Principal Amount: CAD$25,000 |
FOR VALUE RECEIVED Cell MedX Corp., (the “Borrower”) promises to pay on demand to the order of Richard N. Jeffs (the “Lender”) the sum of $25,000 lawful money of Canada (the “Principal Sum”) together with interest on the Principal Sum from July 12, 2017 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.
For the purposes of this promissory note, Interest Rate means 6 per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Principal Sum when the Principal Sum is repaid.
The Borrower may repay the Principal Sum and the Interest in whole or in part at any time.
The Borrower waives presentment, protest, notice of protest and notice of dishonour of this promissory note.
BORROWER
Cell MedX Corp.
Per:
/s/ Yanika Silina
Yanika Silina, CFO
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed as of: | 10/17/17 | None on these Dates | ||
| Filed on: | 10/16/17 | |||
| For Period end: | 8/31/17 | |||
| 7/12/17 | ||||
| List all Filings | ||||